(Q43828848)

27 November 2017

title

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer (English)

1 reference

27 November 2017

1 reference

Gore M

1

1 reference

27 November 2017

Oza A

2

1 reference

27 November 2017

Rustin G

3

1 reference

27 November 2017

Malfetano J

4

1 reference

27 November 2017

Calvert H

5

1 reference

27 November 2017

Clarke-Pearson D

6

1 reference

27 November 2017

Carmichael J

7

1 reference

27 November 2017

Ross G

8

1 reference

27 November 2017

Beckman RA

9

1 reference

27 November 2017

Fields SZ

10

1 reference

27 November 2017

publication date

1 January 2002

1 reference

European Journal of Cancer

27 November 2017

published in

1 reference

27 November 2017

volume

38

1 reference

27 November 2017

issue

1

1 reference

27 November 2017

page(s)

57-63

1 reference

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Ovarian carcinoma. Advances in diagnosis, staging, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Selection of Active Drugs for Ovarian Cancer Based on CA-125 and Standard Response Rates in Phase II Trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Oral topotecan: bioavailablity and effect of food co-administration

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900188-5

7 January 2021

10.1016/S0959-8049(01)00188-5

Identifiers

DOI

1 reference

27 November 2017

1 reference